In a late December 2022 news release from biopharmaceutical company Altimmune, Inc., the company shared that positive topline data was available from a 24-week study—including a 12-week extension—which evaluated…
Dr. Paul Monga, director of Pittsburgh’s Liver Research Center, and his team are studying cancer and liver regeneration. Dr. Monga recently published a study that finds activation of a medication…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Happy Monday! This week, we have details on a sad story of a toddler passing away from very rare mesenchymal chondrosarcoma, new research about the genetic risk factors of non-alcoholic…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Over the last few years, the incidence of nonalcoholic fatty liver disease (NAFLD) has increased rapidly. As a result, many researchers are beginning to pay closer attention to this disease…
The incidence of nonalcoholic fatty liver disease (NAFLD) has been rapidly rising worldwide, with many healthcare providers expressing concern. Because of this rapid growth – and simultaneous problems with underdiagnosis…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
In late June 2022, Patient Worthy discussed how doctors and scientists were concerned about rising rates of nonalcoholic fatty liver disease (NAFLD) in Filipinos. But according to new research, the…
Altogether, an estimated 15-30% of people around the globe have nonalcoholic fatty liver disease (NAFLD), a condition in those who drink very little or not at all which mimics liver…
The Fatty Liver Foundation (FLF) has just announced a new national survey which will document the experiences and needs of individuals living with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic…
A recent study conducted at the Penn State College of Medicine focused in on nonalcoholic fatty liver disease (NAFLD), specifically blood clotting in this rare disorder. These researchers knew that…
Nonalcoholic steatohepatitis is a liver disease, causing fat to build up in the liver. The resulting inflammation may lead to liver cancer or cirrhosis (scarring) and possible liver failure. As…
Fatty Liver Disease This condition is exactly what it sounds like- excess fat accumulates in the liver and causes damage. The condition can have many negative consequences on the body.…
According to a recent article, a low carbohydrate intervention used to reduce type 2 diabetes and for prediabetes regression, may be a treatment option for patients with nonalcoholic fatty liver…
According to a recent article from Physician’s Weekly, two trials recently published are showing the results of striving to improve the management and outcomes in nonalcoholic steatohepatitis (NASH) and…
Currently, there are no FDA-approved treatments for nonalcoholic fatty liver disease (NAFLD) or its more advanced version: nonalcoholic steatohepatitis (NASH). This is partly due to the lack of understanding surrounding…
The first patient in a Phase 2a trial of BOS-580 as a treatment for nonalcoholic steatohepatitis (NASH) was recently dosed. Boston Pharmaceuticals, the developer of the drug, aims to address…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Rare disease patients often face obstacles when it comes to the different aspects of care, whether that's diagnosis, screening, or management. Recent research from Baylor College of Medicine investigated the…
According to a recent report in Medical Xpress, over twenty studies have indicated escalating events of nonalcoholic fatty liver disease (NAFLD) in children worldwide. In the United States, NAFLD heads…
According to Yahoo Finance, D&D Pharmatech has initiated dosing in their Phase 1 trial of DD01, a treatment for nonalcoholic fatty liver disease (NAFLD) and diabetes in obese patients. As…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Fatty liver disease, which can be caused by alcohol consumption or can be unrelated (nonalcoholic fatty liver disease/NAFLD), belongs to a larger group of conditions that have been labeled as…
According to a study from hindawi.com, the serum glycocholic acid (GCA) to total bile acid (TBA) ratio can be used to identify people living with nonalcoholic fatty liver disease (NAFLD).…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
